346 related articles for article (PubMed ID: 21992472)
21. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.
Suardi N; Ficarra V; Willemsen P; De Wil P; Gallina A; De Naeyer G; Schatteman P; Montorsi F; Carpentier P; Mottrie A
Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567
[TBL] [Abstract][Full Text] [Related]
22. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
23. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
24. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
King CR; Presti JC; Gill H; Brooks J; Hancock SL
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
27. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
[TBL] [Abstract][Full Text] [Related]
28. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
[TBL] [Abstract][Full Text] [Related]
29. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy?
Bastide C; Rossi D; Lechevallier E; Bladou F; Barriol D; Bretheau D; Grisoni V; Mancini J; Giusiano S; Eghazarian C; Van Hove A
BJU Int; 2012 Feb; 109(4):525-30; discussion 531-2. PubMed ID: 21851534
[TBL] [Abstract][Full Text] [Related]
30. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
[TBL] [Abstract][Full Text] [Related]
31. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
Schroeck FR; Sun L; Freedland SJ; Albala DM; Mouraviev V; Polascik TJ; Moul JW
BJU Int; 2008 Jul; 102(1):28-32. PubMed ID: 18384634
[TBL] [Abstract][Full Text] [Related]
32. Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml.
Urakami S; Yonese J; Yamamoto S; Yuasa T; Kitsukawa S; Numao N; Kubo Y; Ito M; Sukegawa G; Yasuda Y; Ishikawa Y; Fukui I
Urol Int; 2011; 87(2):175-81. PubMed ID: 21849759
[TBL] [Abstract][Full Text] [Related]
33. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
Ost P; Lumen N; Goessaert AS; Fonteyne V; De Troyer B; Jacobs F; De Meerleer G
Eur Urol; 2011 Oct; 60(4):842-9. PubMed ID: 21514039
[TBL] [Abstract][Full Text] [Related]
34. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.
Bahler CD; Foster RS; Bihrle R; Beck SD; Gardner TA; Sundaram CP; Masterson TA; Cheng L; Koch MO
BJU Int; 2010 May; 105(10):1372-6. PubMed ID: 19863521
[TBL] [Abstract][Full Text] [Related]
36. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
[TBL] [Abstract][Full Text] [Related]
38. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
39. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
40. Race as an independent predictor of outcome after treatment for localized prostate cancer.
Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
